Kadcyla (trastuzumab emtansine)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Breast Cancer
Last updated March 31, 2014
Xiaflex (collagenase clostridium histolyticum)
Status:
Negotiations were not pursued
Manufacturer:
Auxillium Pharmaceuticals Inc.
Indication:
Dupuytren's contracture with a palpable cord
Last updated March 18, 2014
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Advanced Non-Squamous Non-Small Cell Lung Cancer
Last updated February 28, 2014
Oralair (grass pollen allergen extract)
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Allergic Rhinitis
Last updated February 17, 2014
Status:
Negotiations were not pursued
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Hyponatremia, non-hypovolemic
Last updated January 31, 2014
Status:
Negotiations were not pursued
Manufacturer:
Biogen Canada Inc.
Indication:
Multiple Sclerosis, improve walking disability
Last updated January 31, 2014
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Systemic Anaplastic Large Cell Lymphoma
Last updated January 31, 2014
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Systemic lupus erythematosus
Last updated January 31, 2014
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated January 23, 2014
Status:
Negotiations were not pursued
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated January 21, 2014